Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
17
Expiration
Apr 16, 2027
DTE
178d
Moneyness
OTM
Intrinsic
$0.00
IBRX 17 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $0.14 | -44.00% | 16 | 236 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.45 | -32.84% | 4 | 2,431 |
| Mar 19, 2027 | 150d | $0.70 | -29.29% | 25 | 51 |
| Apr 16, 2027 | 178d | $0.75 | -34.21% | 6 | 100 |
| May 21, 2027 | 213d | $1.50 | -6.25% | 3 | 7 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | $2.25 | -8.16% | 2 | 33 |
| Jan 21, 2028 | 458d | $2.82 | +4.44% | 30 | 1,004 |
| Mar 17, 2028 | 514d | $2.70 | +25.58% | 26 | 125 |
| Jan 19, 2029 | 822d | $3.95 | +3.95% | 1 | 16 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.